Your browser doesn't support javascript.
loading
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Yang, Yunpeng; Sun, Jiya; Wang, Zhehai; Fang, Jian; Yu, Qitao; Han, Baohui; Cang, Shundong; Chen, Gongyan; Mei, Xiaodong; Yang, Zhixiong; Ma, Rui; Bi, Minghong; Ren, Xiubao; Zhou, Jianying; Li, Baolan; Song, Yong; Feng, Jifeng; Li, Juan; He, Zhiyong; Zhou, Rui; Li, Weimin; Lu, You; Zhou, Hui; Wang, Shuyan; Sun, Luyao; Puig, Oscar; Mancao, Christoph; Peng, Bo; Fang, Wenfeng; Xu, Wei; Zhang, Li.
Afiliação
  • Yang Y; Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Sun J; New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Wang Z; Medical Oncology Department, Shandong Cancer Hospital, Jinan, People's Republic of China.
  • Fang J; Department of Thoracic Oncology II, Peking University Cancer Hospital, Beijing, People's Republic of China.
  • Yu Q; Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning City, People's Republic of China.
  • Han B; Department of Respiration, Shanghai Chest Hospital, Shanghai, People's Republic of China.
  • Cang S; Department of Oncology, The Henan Province Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
  • Chen G; Department of Respiration, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
  • Mei X; Department of Respiration, Anhui Provincial Hospital, Hefei, People's Republic of China.
  • Yang Z; Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, People's Republic of China.
  • Ma R; Medical Oncology Department of Thoracic Cancer, Liaoning Cancer Hospital, Shenyang, People's Republic of China.
  • Bi M; Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China.
  • Ren X; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
  • Zhou J; Department of Respiratory Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
  • Li B; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Song Y; Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, People's Republic of China.
  • Feng J; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China.
  • Li J; Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, People's Republic of China.
  • He Z; Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, People's Republic of China.
  • Zhou R; Department of Respiration, Xiangya Second Hospital, Changsha, People's Republic of China.
  • Li W; Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Lu Y; Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Zhou H; Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Wang S; Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Sun L; Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Puig O; Translational Medicine, Oncology Business Unit, Eli Lilly and Company, New York, New York.
  • Mancao C; New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Peng B; New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Fang W; Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
  • Xu W; New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, People's Republic of China.
  • Zhang L; Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. Electronic address: zhangli@sysucc.org.cn.
J Thorac Oncol ; 16(12): 2109-2120, 2021 12.
Article em En | MEDLINE | ID: mdl-34358724
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Platina / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Platina / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2021 Tipo de documento: Article